高级检索
当前位置: 首页 > 详情页

Ginsenoside Rg2 protects cardiomyocytes against trastuzumab-induced toxicity by inducing autophagy

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE ◇ 预警期刊

机构: [1]Hebei Med Univ, Dept Cardiovasc Med, Shijiazhuang, Hebei, Peoples R China [2]Hebei Gen Hosp, Dept Cardiovasc Med, 348 West Heping Rd, Shijiazhuang 050000, Hebei, Peoples R China [3]Hebei Med Univ, Affiliated Hosp 4, Dept Cardiovasc Med, Shijiazhuang 050000, Hebei, Peoples R China
出处:
ISSN:

关键词: trastuzumab ginsenoside Rg2 apoptosis autophagy

摘要:
Trastuzumab (TZM) significantly improves the outcomes of patients with breast cancer; however, it is associated with severe cardiotoxicity. Ginsenoside Rg2 was reported to exert protective effects against myocardial injury and apoptosis in human cardiomyocytes (HCMs). However, whether ginsenoside Rg2 protects HCMs against TZM-induced toxicity remains unclear. The present study investigated the proliferation of HCMs using a Cell Counting Kit-8 assay and Ki67 immunofluorescence staining. Apoptotic cells were detected by Annexin V/propidium iodide staining and flow cytometry. Furthermore, monodansylcadaverine staining was performed to detect cell autophagy. In addition, western blotting was used to detect the expression levels of phosphorylated (p)-Akt, p-mTOR, beclin 1, microtubule associated protein 1 light chain 3 alpha (LC3) and autophagy protein 5 (ATG5) in HCMs. Pretreatment with ginsenoside Rg2 significantly protected HCMs against TZM-induced cytotoxicity by inhibiting apoptosis. Furthermore, pretreatment with ginsenoside Rg2 induced autophagy in HCMs by upregulating the expression levels of p-Akt, p-mTOR, beclin 1, LC3 and ATG5. The results obtained in the present study suggested that ginsenoside Rg2 could protect HCMs against TZM-induced cardiotoxicity by activating autophagy. Therefore, ginsenoside Rg2 may serve as a potential therapeutic agent to prevent TZM-related cardiotoxicity in patients with breast cancer.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
JCR分区:
出版当年[2021]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2024]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Dept Cardiovasc Med, Shijiazhuang, Hebei, Peoples R China
通讯作者:
通讯机构: [2]Hebei Gen Hosp, Dept Cardiovasc Med, 348 West Heping Rd, Shijiazhuang 050000, Hebei, Peoples R China [*1]Department of Cardiovascular Medicine, Hebei General Hospital, 348 West Heping Road, Shijiazhuang, Hebei 050000, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号